BCR Diagnostics

BCR Diagnostics is a medical technology company focused on the development of rapid phenotypic antimicrobial susceptibility testing (AST) solutions for infectious diseases. The company's proprietary platform, based on technology licensed from Beth Israel Deaconess Medical Center, is designed to identify pathogens and determine their antibiotic resistance profiles directly from clinical samples in a fraction of the time required by traditional culture-based methods. By providing actionable results in hours rather than days, BCR Diagnostics enables clinicians to transition from broad-spectrum to targeted antibiotic therapy more quickly, which is critical for improving outcomes in patients with sepsis and bloodstream infections. The company's approach supports global antimicrobial stewardship efforts by reducing the unnecessary use of broad-spectrum antibiotics and helping to combat the rise of multi-drug resistant organisms. BCR Diagnostics is headquartered in Providence, Rhode Island, and has received support from the Slater Technology Fund.